Esperion Therapeutics (ESPR)

• Market cap: $189M
• 1 day: 4.12%
• 5 days: 5.09%
• 1 month: -30.60%
• 3 months: -44.78%
• 6 months: -53.08%
• Year to date: -54.57%
• 1 year: -49.27%
• 5 years: -97.48%
• 10 years: -98.95%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Employees: 240

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

30% more capital invested

Capital invested by funds: $214M [Q3] → $277M (+$63.3M) [Q4]

26% more call options, than puts

Call options by funds: $5.22M | Put options by funds: $4.13M

22% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 45

3% more funds holding

Funds holding: 182 [Q3] → 188 (+6) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

1.73% less ownership

Funds ownership: 68.23% [Q3] → 66.5% (-1.73%) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 200% upside
• Avg. target: $6.40 540% upside
• High target: $16 1,501% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target	1,501% upside $16	Buy Reiterated	25 Apr 2025
Needham Serge Belanger 50% 1-year accuracy 63 / 125 met price target	400% upside $5	Buy Reiterated	25 Apr 2025
Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target	200% upside $3	Neutral Maintained	17 Apr 2025
Citizens Capital Markets Jason Butler 29% 1-year accuracy 12 / 41 met price target	300% upside $4	Market Outperform Reiterated	5 Mar 2025
JMP Securities Roy Buchanan 21% 1-year accuracy 5 / 24 met price target	300% upside $4	Market Outperform Reiterated	11 Feb 2025